|
Subgroup
|
Metoclopramide group (
n
= 100)
|
Domperidone group (
n
= 99)
|
Control group (
n
= 99)
|
Total (
n
= 298)
|
P
value
|
|---|
|
Age
| | | | | |
|
<60 years
|
22/38 (57.9)*
|
19/35 (54.3)*
|
11/41 (26.8)
|
52/114 (45.6)
|
0.0100
|
|
≥60 years
|
33/62 (53.2)*
|
32/64 (50.0)*
|
16/58 (27.6)
|
81/184 (44.0)
|
0.0090
|
|
Sex
| | | | | |
|
Male
|
38/67 (56.7)**
|
28/58 (48.3)*
|
17/72 (23.6)
|
83/197 (42.1)
|
0.0002
|
|
Female
|
17/33 (51.5)
|
23/41 (56.1)
|
10/27 (37.0)
|
50/101 (49.5)
|
0.2944
|
|
APACHE II score
| | | | | |
|
< 20
|
31/45 (68.9)**
|
27/43 (62.8)*
|
14/43 (32.6)
|
72/131 (55.0)#
|
0.0013
|
|
≥ 20
|
24/55 (43.6)
|
24/56 (42.9)
|
13/56 (23.8)
|
61/167 (36.5)
|
0.0398
|
|
SOFA score
| | | | | |
|
< 12
|
39/66 (59.1)*
|
37/68 (54.4)‡
|
24/66 (36.4)
|
100/200 (50.0)†
|
0.0221
|
|
≥ 12
|
16/34 (47.1)**
|
14/31 (45.2)**
|
3/33 (9.1)
|
33/98 (33.7)
|
0.0012
|
|
Neurological diseases
| | | | | |
|
Yes
|
27/48 (56.3)**
|
19/41 (46.3)∫
|
9/39 (23.1)
|
55/128 (43.0)
|
0.0069
|
|
No
|
28/52 (53.8)*
|
32/58 (55.2)*
|
18/60 (30.0)
|
78/170 (45.9)
|
0.0089
|
|
Sepsis
| | | | | |
|
Yes
|
9/14 (64.3)*
|
7/11 (63.6)*
|
2/13 (15.4)
|
18/38 (47.4)
|
0.0173
|
|
No
|
46/86 (53.5)**
|
44/88 (50.0)*
|
25/86 (29.1)
|
115/260 (44.2)
|
0.0023
|
|
Use of sedatives or analgesics
| | | | | |
|
Yes
|
15/35 (42.9)
|
16/37 (43.2)
|
12/38 (31.6)
|
43/110 (39.1)
|
0.5023
|
|
No
|
40/65 (61.5)**
|
35/62 (56.5)**
|
15/61 (24.6)
|
90/188 (47.9)
|
0.0001
|
|
Use of vasopressors
| | | | | |
|
Yes
|
10/24 (41.7)
|
8/21 (38.1)
|
4/25 (16.0)
|
22/70 (31.4)¶
|
0.1129
|
|
No
|
45/76 (59.2)**
|
43/78 (55.1)**
|
23/74 (31.1)
|
111/228 (48.7)
|
0.0009
|
|
Mechanical ventilation
| | | | | |
|
Yes
|
33/72 (45.8)
|
31/66 (47.0)
|
19/68 (27.9)
|
83/206 (40.3)‖
|
0.0397
|
|
No
|
22/28 (78.6)**
|
20/33 (60.6)*
|
8/31 (25.8)
|
50/92 (54.3)
|
0.0002
|
- Data presented as success/total (%). APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment. *P <0.016, metoclopramide or domperidone group versus controls. **P <0.0033, metoclopramide or domperidone group versus controls. #
P = 0.0015, APACHE II score <20 versus ≥20. ‡
P = 0.0360, SOFA <12 in the domperidone group versus controls. †
P = 0.0077, SOFA score <12 versus ≥12. ∫
P = 0.0292, neurologic diseases in the domperidone group versus controls. ¶
P = 0.0111, use of vasopressors versus without vasopressor. ‖
P = 0.0241, mechanical ventilation versus no ventilation.
